Stockpolly
Search
Delisting risk
NCNA · NASDAQ · Biotechnology

NuCana (ADR) (NCNA)

Develops ProTide oncology candidates that redesign nucleoside agents for cancer cells.

$1.38
Pre-market−0.03 (−2.09%)
At close$1.41(+1.81%)
Watchlist

In millions of USD, except per-share figures · converted from GBP at the latest rate

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
11121111714161665
Research & development10999512103243
222221162122
General & administrative222221162120
Other expenses−11000−100−4200
Operating income−11−12−11−11−7−1−4−16−1−6−6−5
0000000−170300
Interest income000000000000
Other non-operating income1−10001004−200
Income before tax−11−12−11−11−7−1−4−33−1−4−6−5
Income tax expense−2−2−2−2−100000−10
Net income from continuing operations−9−10−9−9−6−1−3−330−3−5−4
Net income−9−10−9−9−6−1−3−330−3−5−4
EPS, basic−$1.69−$1,223.56−$1,091.96−$1,051.12−$655.01−$39.87−$138.42−$41.98−$0.18−$1.08−$1.73−$1.03
EPS, diluted−$1.69−$1,223.56−$1,091.96−$1,051.12−$655.01−$39.87−$138.42−$41.98−$0.18−$1.08−$1.73−$1.03
Weighted average shares, basic500000014444
Weighted average shares, diluted500000014444
EBITDA−12−11−11−11−7−2−4−16−5−4−6−5
Depreciation & amortization000000000000
EBIT−12−11−11−11−7−2−4−16−5−4−6−5